Wall Street brokerages predict that Allakos Inc (NASDAQ:ALLK) will report ($0.38) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Allakos’ earnings. The firm is scheduled to report its next earnings results on Thursday, February 14th.
On average, analysts expect that Allakos will report full year earnings of ($1.23) per share for the current fiscal year, with EPS estimates ranging from ($1.26) to ($1.20). For the next year, analysts anticipate that the firm will post earnings of ($1.49) per share, with EPS estimates ranging from ($1.50) to ($1.48). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Allakos.
Allakos (NASDAQ:ALLK) last announced its earnings results on Thursday, November 8th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10).
Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. bought a new stake in shares of Allakos in the third quarter valued at approximately $30,698,000. TIAA CREF Investment Management LLC bought a new stake in shares of Allakos in the third quarter valued at approximately $746,000. Teachers Advisors LLC bought a new stake in shares of Allakos in the third quarter valued at approximately $725,000. MetLife Investment Advisors LLC bought a new stake in shares of Allakos in the third quarter valued at approximately $434,000. Finally, Redmile Group LLC bought a new stake in shares of Allakos in the third quarter valued at approximately $65,681,000. 16.92% of the stock is owned by institutional investors.
Allakos stock traded down $2.47 during trading hours on Friday, reaching $58.91. 194,278 shares of the company were exchanged, compared to its average volume of 125,275. Allakos has a 12 month low of $26.00 and a 12 month high of $62.00.
Allakos Company Profile
Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
Featured Story: Return on Investment (ROI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.